RIPK3 and neoplasm: Overall, this set of experiments shows that apoptotic drug-tolerant persisters bear molecular features of vulnerability to necroptosis (increased RIPK3 expression and reduced C8 activity), that could possibly be used to effectively kill resistant tumor cells to repeated treatments.